EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy

Dayangku Nordiyana B P Hassanel, Ankur Sharma

Clinical and Molecular Hepatology · 01.04.2026 · 32 (2) · 620-645

DOI: 10.3350/cmh.2025.1410 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2026. Verfasst von Dayangku Nordiyana B P Hassanel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Translational Genomics Program, Garvan Institute of Medical Research, Darlinghurst, Australia. Hauptthemen laut MEDLINE: Cancer Vaccines, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Centenary Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer mortality worldwide. Its pathogenesis reflects a combination of tumour-intrinsic heterogeneity and a profoundly immunosuppressive tumour microenvironment. Growing evidence shows that tumours recapitulate developmental programs to establish an oncofetal ecosystem, characterised by the re-expression of foetal antigens and foetal-like stromal and immune subsets. These features drive immune evasion and shape therapeutic response, contributing to immunotherapy outcomes in clinic. This review outlines mechanistic insights into oncofetal reprogramming across tumour, stromal, and immune compartments and evaluates therapeutic strategies that target these dependencies. We highlight emerging vaccine platforms, cellular therapies, and biologics targeting oncofetal antigens, with particular emphasis on mRNA–lipid nanoparticle vaccines and their potential to induce robust, durable antitumour immunity. We further discuss rational combinatorial strategies that integrate vaccines with immune checkpoint inhibitors. Finally, we discuss how overcoming liver tolerance and antigenic heterogeneity will be essential for effective oncofetal-directed therapies. Collectively, targeting the oncofetal ecosystem through coordinated vaccine, cellular, and immunotherapeutic strategies offers a path toward more durable responses and broader immunotherapy benefits in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesCarcinoma, HepatocellularLiver NeoplasmsHumansImmunotherapyAntigens, NeoplasmTumor MicroenvironmentAnimalsCellular Reprogramming

Stichwörter der Autor:innen

Hepatocellular carcinomaImmunotherapyOncofetal reprogrammingVaccinesmRNA therapeutics

Substanzen

Cancer VaccinesAntigens, Neoplasmoncofetal antigens

Autor:innen und Institutionen

  • Translational Genomics Program, Garvan Institute of Medical Research, Darlinghurst, Australia.
  • St. Vincent's Clinical School, Faculty of Medicine and Health, University of New South Wales, Darlinghurst, Australia.
  • KK Research Centre, KK Women's and Children's Hospital, Singapore.

Förderung

  • CSL Centenary Fellowship

Zitieren

APA

Hassanel, D. N. B. P., & Sharma, A. (2026). Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy. Clinical and Molecular Hepatology, 32(2), 620-645. https://doi.org/10.3350/cmh.2025.1410

Vancouver

Hassanel DNBP, Sharma A. Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy. Clinical and Molecular Hepatology. 2026;32(2):620-645. doi:10.3350/cmh.2025.1410

BibTeX
@article{Hassanel2026,
  author = {Hassanel, Dayangku Nordiyana B P and Sharma, Ankur},
  title = {Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {620--645},
  doi = {10.3350/cmh.2025.1410}
}
Kostenlos starten →